Physician profile
Angela Patrick
NPI 1780068833
$7,300.20
in general payments reported to CMS, 2019-2025
54 companies · $2,437 in 2025
The $2,437 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,293 · 2022: $1,152 · 2023: $1,270 · 2024: $1,149 · 2025: $2,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,561 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,560.98 |
| Education | $293.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $525.35 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $461.89 | 2021-2025 | Calquence, Imfinzi, Enhertu |
| Merck Sharp & Dohme LLC | $384.47 | 2021-2025 | Keytruda, Reblozyl, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $382.74 | 2021-2025 | Ninlaro, Iclusig, Alunbrig |
| Gilead Sciences, INC. | $375.90 | 2022-2025 | Trodelvy |
| Accord Healthcare, INC. | $366.73 | 2023-2025 | Camcevi |
| Pfizer INC. | $339.11 | 2021-2025 | |
| Astellas Pharma US INC | $304.89 | 2021-2025 | Xtandi, Padcev |
| Amgen INC. | $297.67 | 2021-2023 | Lumakras, Vectibix, Nplate |
| Glaxosmithkline, LLC. | $296.11 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Abbvie INC. | $286.02 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $248.01 | 2021-2023 | Opdualag, Opdivo |
| Lilly USA, LLC | $247.18 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $221.13 | 2021-2023 | Padcev |
| Pharmacyclics LLC, An Abbvie Company | $191.40 | 2021-2023 | Imbruvica |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $172.30 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Beone Medicines USA, INC. | $153.39 | 2025 | Brukinsa |
| Adc Therapeutics America, INC. | $141.80 | 2022-2025 | |
| Janssen Biotech, INC. | $139.73 | 2022-2025 | Darzalex, Talvey, Tecvayli |
| Celgene Corporation | $133.47 | 2022-2025 | Reblozyl, Pomalyst |
| Daiichi Sankyo INC. | $114.92 | 2021-2025 | Enhertu |
| Beigene USA, INC. | $113.84 | 2021-2025 | Brukinsa |
| Springworks Therapeutics, INC. | $100.84 | 2024-2025 | Ogsiveo |
| Exelixis INC. | $95.00 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $92.41 | 2021-2025 | Onivyde |
| Regeneron Healthcare Solutions, INC. | $72.49 | 2022-2025 | Lynozyfic |
| Sobi, INC | $66.63 | 2022-2025 | |
| Eisai INC. | $64.90 | 2023-2025 | |
| Genzyme Corporation | $64.75 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $63.72 | 2021-2025 | |
| G1 Therapeutics, INC. | $59.54 | 2022-2023 | Cosela |
| Bayer Healthcare Pharmaceuticals INC. | $55.16 | 2021-2023 | |
| Deciphera Pharmaceuticals INC. | $54.08 | 2024-2025 | Qinlock, Romvimza |
| Aveo Pharmaceuticals, INC. | $52.57 | 2021-2025 | |
| Morphosys, US INC. | $47.45 | 2021-2023 | Monjuvi |
| Cti Biopharma Corp. | $41.49 | 2022-2023 | Vonjo |
| Servier Pharmaceuticals LLC | $38.98 | 2025 | |
| Emd Serono, INC. | $38.91 | 2023 | Bavencio |
| Tersera Therapeutics LLC | $36.90 | 2025 | Xermelo |
| Janssen Pharmaceuticals, INC | $32.83 | 2021 | |
| Kite Pharma, INC. | $32.52 | 2024-2025 | Yescarta |
| Incyte Corporation | $28.17 | 2021-2024 | Jakafi |
| Immunocore Limited | $26.75 | 2025 | Kimmtrak |
| Adaptive Biotechnologies Corporation | $26.01 | 2025 | Clonoseq |
| Genmab U.S., INC. | $25.00 | 2023 | Epkinly |
| Tolmar Pharmaceuticals, INC. | $23.78 | 2022 | |
| Recordati_rare_diseases_inc. | $23.74 | 2024 | Sylvant |
| Pharmacosmos Therapeutics INC. | $23.47 | 2021 | |
| Genentech USA, INC. | $21.18 | 2024 | Alecensa, Tecentriq |
| Abbott Laboratories | $20.88 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Novocure INC. | $20.83 | 2025 | Optune Lua (Novottf-200t) |
| Alexion Pharmaceuticals, INC. | $19.66 | 2023 | Ultomiris |
| Amag Pharmaceuticals, INC. | $16.95 | 2021 | |
| Global Blood Therapeutics, INC. | $14.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Patrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.